JACKSONVILLE, Fla. — A new study by Mayo Clinic researchers may have broad implications for treatment of patients with predominantly benign thyroid disease and newly treated hypothyroidism.

The study, to be published in Mayo Clinic Proceedings in July, looked at whether generic and brand-name levothyroxine therapy affected hospitalization for cardiovascular events for those patients who are more at risk of coronary heart disease and heart failure. Levothyroxine is the most prescribed medication in the U.S., with more than 23 million prescriptions written annually.

The retrospective analysis, using deidentified claims data from a large private U.S. health plan, found that cardiovascular event rates were similar for generic and brand-name levothyroxine therapy, with lower pharmacy costs for the generic drug. The findings, if confirmed with research into longer-term event rates, suggest that generic or brand-name levothyroxine may be used to treat hypothyroidism due to benign thyroid disorders. The average 30-day cost of the generic drug was about half the cost of brand-name medication for patients and insurers.

"More than 90% of thyroid prescriptions are for levothyroxine, and there has been disagreement as to whether generic levothyroxine and branded thyroxine preparations are equivalent," says Robert Smallridge, M.D., a Mayo Clinic endocrinologist and the study's principal investigator. "These findings suggest that generic and brand levothyroxine therapy are similar as related to cardiovascular events risk."

Dr. Smallridge says the findings require confirmation with longer-term follow-up and study of subsets of patients, such as those with a history of thyroid cancer, who frequently receive higher doses of levothyroxine.

Hypothyroidism, or underactivity of the thyroid gland, affects the function of many organs in the body, elevating blood cholesterol levels and increasing the risk of heart attacks, heart failure and stroke. Levothyroxine is used to reduce elevated cholesterol and reverse symptoms of hypothyroidism. U.S. brand names for levothyroxine include Levothroid, Levoxyl, Synthroid, Tirosint and Unithroid.

The analysis was unusual in that it used information from an administrative claims database provided by OptumLabs Data Warehouse. OptumLabs was co-founded by Optum Inc. and Mayo Clinic in 2012. This data warehouse contains deidentified administrative claims data, as well as deidentified electronic health record data from a nationwide network of provider groups.

The study reviewed records for 87,902 patients followed for a mean period of one year, focusing on hospitalization for heart attacks, congestive heart failure, atrial fibrillation or strokes. The analysis found no difference in event rates for the four types of cardiovascular events.

Dr. Smallridge is the Alfred D. and Audrey M. Petersen Professor of Cancer Research and deputy director of the Mayo Clinic Cancer Center in Jacksonville. The study was funded by the Mayo Clinic Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, with an additional gift from Alfred D. and Audrey M. Petersen.

Watch: Dr. Smallridge shares more about hypothyroidism, the study and the results. Sound bites available for download.

###

About Mayo Clinic Proceedings
Mayo Clinic Proceedings is a monthly peer-reviewed medical journal that publishes original articles and reviews dealing with clinical and laboratory medicine, clinical research, basic science research, and clinical epidemiology. Proceedings is sponsored by the Mayo Foundation for Medical Education and Research as part of its commitment to physician education. It publishes submissions from authors worldwide. The journal has been published for more than 80 years and has a circulation of 130,000. Visit the Mayo Clinic Proceedings website to view articles.

About Mayo Clinic 
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, comprehensive care to everyone who needs healing. Learn more about Mayo Clinic. Visit the Mayo Clinic News Network. 

Media contact:

• Tia Ford, Mayo Clinic Public Affairs, 904-953-0746, newsbureau@mayo.edu

Related Articles